Tildrakizumab for the treatment of psoriasis

References

• Yiu ZZ, Warren R. Efficacy and safety of emerging immunotherapies in psoriasis. Immunotherapy. 2015;7(2):119–133.
   PubMed Web of Science ®Google Scholar
• Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645–653.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Del Giglio M, Girolomoni G. Treatment approaches to moderate to severe psoriasis. Int J Mol Sci. 2017;18(11):2427.
   PubMed Web of Science ®Google Scholar
• Menter A, Griffiths CEM. Current and future management of psoriasis. The Lancet. 2007;370(9583):272–284.
   PubMed Web of Science ®Google Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. J Am Acad Dermatol. 2009;61(3):451–485.
   PubMed Web of Science ®Google Scholar
• Yélamos O, Puig L. Systemic methotrexate for the treatment of psoriasis. Expert Rev Clin Immunol. 2015;11(5):553–563.
   PubMed Web of Science ®Google Scholar
• Kerkhof P. Therapeutic strategies: rotational therapy and combinations. Clin Exp Dermatol. 2001;26(4):356.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, D’adamio S, Bianchi L, et al. Tildrakizumab for treating psoriasis. Expert Opin Biol Ther. 2017;17(5):645–657.
   PubMed Web of Science ®Google Scholar
• Beck KM, Sanchez IM, Yang EJ, et al. Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date. Psoriasis: Targets and Therapy. 2018;8:49–58.
   Web of Science ®Google Scholar
• Markham A. Tildrakizumab: first global approval. Drugs. 2018;78(8):845–849.
   Web of Science ®Google Scholar
• Sun Pharma announces receipt of European Commission Approval For ILUMETRI® (tildrakizumab) by Almirall for treatment of moderate-to-severe chronic plaque psoriasis Mumbai, India: Sun Pharmaceutical Industries Ltd; 2018 [cited 2018 Oct 26]. Available from: file:///C:/Users/Selva/Downloads/Press%20Release%20European%20Commission%20Approval%20For%20ILUMETRI.pdf
   Google Scholar
• Sun Pharma announces Australian TGA approval of ILUMYA™ (tildrakizumab) for treatment of moderate-to-severe plaque psoriasis Mumbai, India: Sun Pharmaceutical Industries Ltd.; 2018 [cited 2018 Oct 26]. Available from: file:///C:/Users/Selva/Downloads/Press%20Release%20Australian%20TGA%20approval%20of%20ILUMYA%20(3).pdf
   Google Scholar
• Torres T, Filipe P. Small molecules in the treatment of psoriasis. Drug Development Research. 2015 Aug;76(5):215–227.
   Google Scholar
• Bilal J, Berlinberg A, Bhattacharjee S, et al. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. J Dermatol Treat. 2018;29(6):569–578.
   PubMed Web of Science ®Google Scholar
• Turbeville JG, Patel NU, Cardwell LA, et al. Recent advances in small molecule and biological therapeutic approaches in the treatment of psoriasis. Clin Pharmacol Ther. 2017;102(1):70–85.
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. The Lancet. 2005;366(9494):1367–1374.
   PubMed Web of Science ®Google Scholar
• Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152(6):1304–1312.
   PubMed Web of Science ®Google Scholar
• Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106–115.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis — results of two phase 3 trials. New England J Med. 2014;371(4):326–338.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Duffin KC, Bissonnette R, et al. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. New England J Med. 2015;373(2):136–144.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. New England J Med. 2015;373(14):1318–1328.
   PubMed Web of Science ®Google Scholar
• Hohenberger M, Cardwell LA, Oussedik E, et al. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. J Dermatol Treat. 2018;29(1):13–18.
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). The Lancet. 2008;371(9625):1665–1674.
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). The Lancet. 2008;371(9625):1675–1684.
   PubMed Web of Science ®Google Scholar
• Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. New England J Med. 2007;356(6):580–592.
   PubMed Web of Science ®Google Scholar
• Ohtsuki M, Kubo H, Morishima H, et al. Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study. J Dermatol. 2018;45(9):1053–1062.
   Web of Science ®Google Scholar
• Bachelez H, van de Kerkhof PCM, Strohal R, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. The Lancet. 2015;386(9993):552–561.
   PubMed Web of Science ®Google Scholar
• Wolk R, Armstrong EJ, Hansen PR, et al. Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis. J Clin Lipidol. 2017;11(5):1243–1256.
   PubMed Web of Science ®Google Scholar
• Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo‐controlled dose‐ranging study. Br J Dermatol. 2012;167(3):668–677.
   PubMed Web of Science ®Google Scholar
• Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and safety trial evaluating the effects of apremilast in psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73(1):37–49.
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. The Lancet. 2017;390(10091):276–288.
   PubMed Web of Science ®Google Scholar
• Merck Sharp & Dohme Corp. Tildrakizumab-asmn (ILUMYATM). US prescribing information. 2018 [cited 2018 Jul 01]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761067s000lbl.pdf.
   Google Scholar
• Chan TC, Hawkes JE, Krueger JG. Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment. Ther Adv Chronic Dis. 2018;9(5):111–119.
   PubMed Web of Science ®Google Scholar
• Khalilieh S, Hodsman P, Xu C, et al. Pharmacokinetics of Tildrakizumab (MK-3222), an Anti-IL-23 monoclonal antibody, after intravenous or subcutaneous administration in healthy subjects. Basic Clin Pharmacol Toxicol. 2018;123:294–300.
   PubMed Web of Science ®Google Scholar
• Kopp T, Riedl E, Bangert C, et al. Clinical improvement in psoriasis with specific targeting of interleukin-23. Nature. 2015 online;521:222.
   PubMed Web of Science ®Google Scholar
• Zandvliet A, Glasgow S, Horowitz A, et al. Tildrakizumab, a novel anti-IL-23 monoclonal antibody, is unaffected by ethnic variability in Caucasian, Chinese, and Japanese subjects. Int J Clin Pharmacol Ther. 2015;53(2):139.
   PubMed Web of Science ®Google Scholar
• Khalilieh S, Hussain A, Montgomery D, et al. Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis. Br J Clin Pharmacol. 2018;84(10):2292–2302.
   PubMed Web of Science ®Google Scholar
• Papp K, Thaçi D, Reich K, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015;173(4):930–939.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Kimball A, Papp K, et al. editors. Impact of body weight on efficacy of tildrakizumab at week 12 in moderate to severe chronic plaque psoriasis. Dermcoll: AB289: Australasian journal of dermatology; 2018.
   Google Scholar
• Blauvelt A, Sofen H, Papp K, et al. AB0955 Tildrakizumab efficacy over time by week 28 response levels in two phase 3 clinical trials in patients with chronic plaque psoriasis. Ann Rheum Dis. 2018;77(Suppl 2):1602–1603.
   Google Scholar
• Papp K, Reich K, Blauvelt A, et al. Clinical efficacy or tildrakizumab in patients with chronic plaque psoriasis over 2 years of treatment: results from long-term extensions to 2 phase 3 clinical studies. SKIN J Cutan Med. 2018;2:S1.
   Google Scholar
• Blauvelt A, Reich K, Papp KA, et al. Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomised controlled trials. Br J Dermatol. 2018;179(3):615–622.
   PubMed Web of Science ®Google Scholar
• Reich K, Papp K, Thaçi D, et al. Safety and tolerability of tildrakizumab, an anti–interleukin-23p19 monoclonal antibody, in patients with chronic plaque psoriasis over two years of treatment: results from long-term extensions of two phase III clinical studies (reSURFACE 1 and reSURFACE 2). J Am Acad Dermatol. 2018;79(3):AB251.
   Web of Science ®Google Scholar